Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension

Z. Ramík, J. Václavík, T. Kvapil, L. Jelínek, E. Kociánová, M. Kamasová, K. Benešová, J. Jarkovský, M. Drápela, Z. Lys

. 2024 ; 33 (1) : 2353836. [pub] 20240607

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013278

Objectives: Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. Methods: Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. Results: Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 vs. -0.65 mL/min/1.73 m2 per year; difference in slope, 0.83 mL/min/1.73 m2 per year; 95% confidence interval [CI]: 0.25-1.41, p = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. Conclusions: Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013278
003      
CZ-PrNML
005      
20240905133327.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/08037051.2024.2353836 $2 doi
035    __
$a (PubMed)38847517
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ramík, Zdeněk $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000336082653
245    10
$a Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension / $c Z. Ramík, J. Václavík, T. Kvapil, L. Jelínek, E. Kociánová, M. Kamasová, K. Benešová, J. Jarkovský, M. Drápela, Z. Lys
520    9_
$a Objectives: Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. Methods: Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. Results: Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 vs. -0.65 mL/min/1.73 m2 per year; difference in slope, 0.83 mL/min/1.73 m2 per year; 95% confidence interval [CI]: 0.25-1.41, p = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. Conclusions: Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a hypertenze $x patofyziologie $x farmakoterapie $x komplikace $7 D006973
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rizikové faktory $7 D012307
650    _2
$a senioři $7 D000368
650    _2
$a retrospektivní studie $7 D012189
650    12
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a progrese nemoci $7 D018450
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a ledviny $x patofyziologie $7 D007668
650    _2
$a následné studie $7 D005500
655    _2
$a časopisecké články $7 D016428
700    1_
$a Václavík, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000178470967 $7 xx0169228
700    1_
$a Kvapil, Tomáš $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Jelínek, Libor $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Exercise Medicine and Cardiovascular Rehabilitation, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000206128270
700    1_
$a Kociánová, Eva $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/000000032183957X
700    1_
$a Kamasová, Monika $u Faculty of Medicine, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000227946512
700    1_
$a Benešová, Klára $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000330431533
700    1_
$a Jarkovský, Jiří $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000214000111
700    1_
$a Drápela, Martin $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Lys, Zdeněk $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000187792191
773    0_
$w MED00000810 $t Blood pressure $x 1651-1999 $g Roč. 33, č. 1 (2024), s. 2353836
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38847517 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133321 $b ABA008
999    __
$a ok $b bmc $g 2143229 $s 1225144
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 33 $c 1 $d 2353836 $e 20240607 $i 1651-1999 $m Blood pressure $n Blood Press $x MED00000810
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace